What Are the Long-Term Side Effects of Reclast Infusion?

Reclast (zoledronic acid) is generally well tolerated for osteoporosis, with its most frequent side effects being short-lived flu-like symptoms after infusion that tend to fade with each subsequent dose.¹ The longer-term picture, though, is more layered. With years of use, rare but serious complications can emerge, including jawbone damage, unusual fracture patterns, kidney stress, and heart rhythm changes. Understanding these risks means understanding which ones depend on how long you stay on the drug, who is most vulnerable, and when taking a break from treatment might make sense.

The Acute Phase Reaction and Whether It Lingers

Most people who receive their first Reclast infusion experience what clinicians call an acute phase reaction: fever, muscle aches, joint pain, headache, and general flu-like malaise that typically starts within the first day or two and clears up within three days. Musculoskeletal pain is one of the most commonly reported symptoms in this window.² These reactions are driven by a burst of inflammatory activity, particularly involving a subset of immune cells called gamma-delta T cells. In people who have a strong acute phase reaction after that first infusion, researchers have found lasting immune shifts: a roughly 30 percent drop in gamma-delta T cells, an 11 percent drop in total lymphocytes, and a 27 percent decrease in eosinophils that persisted at one year.³ Whether these immune shifts have any clinical consequences remains unclear, but they do show that a single infusion can leave a measurable immunological footprint well beyond the first few days.

The good news is that the acute symptoms themselves diminish significantly with each subsequent annual infusion. If your first dose hit hard, the second is usually milder, and by the third, most people barely notice it.

Jaw Osteonecrosis

Medication-related osteonecrosis of the jaw (MRONJ) is probably the side effect people worry about most when they hear “bisphosphonate.” It involves an area of jawbone that becomes exposed through the gum tissue and fails to heal, sometimes leading to pain, infection, and tissue breakdown. The risk with Reclast given once yearly for osteoporosis is low, estimated at roughly 0.017 percent, or about 1.7 cases per 10,000 patients.⁴ That is a genuinely small number, but it is not zero, and certain factors push the risk higher.

The cases that do occur tend to cluster around dental procedures. In one case series, all four patients had undergone surgery of the jaw or surrounding bone while on or shortly after stopping zoledronic acid, and all had a prior history of long-term oral bisphosphonate use before switching to Reclast.⁴ That combination, years of oral bisphosphonate therapy followed by intravenous zoledronic acid, appears to compound the risk. If you are planning dental implants, extractions, or jaw surgery, your dentist and prescribing physician should coordinate timing carefully.

Atypical Femoral Fractures

Bisphosphonates work by slowing the natural process of bone remodeling, which is exactly what makes them effective against osteoporosis. But over many years, suppressing that turnover too aggressively can leave bone that looks dense on a scan yet is more brittle in a specific way. The result, in rare cases, is an atypical femoral fracture: a stress fracture along the shaft of the thighbone that can occur with minimal trauma, sometimes preceded by a dull ache in the thigh for weeks or months beforehand.

A large study of bisphosphonate users found that the risk of atypical femoral fractures climbed steeply with duration of use. Compared with people who used bisphosphonates for less than three months, those who used them for three to five years had a roughly ninefold higher risk, while use for eight years or more was associated with a more than 40-fold increase.⁵ Those hazard ratios sound alarming on their own, but it is worth keeping context in mind: the baseline rate of atypical fractures is extremely low, so even a 40-fold increase of a very small number remains a small number. A separate study specifically tracking zoledronate users found that none of them developed atypical femoral fractures during the study period, though the number of zoledronate users in that dataset was small.⁶

When bone remodeling has been suppressed for years and the drug is then stopped, osteoclast activity can rebound. This rebound is one proposed explanation for why some atypical fractures appear after discontinuation rather than during active treatment. The fractures tend to occur in the subtrochanteric region, are sometimes bilateral, and can take longer than typical fractures to heal.

How Reclast Affects the Kidneys

Zoledronic acid is cleared by the kidneys, which is why all bisphosphonates carry warnings against use in people with severe kidney impairment, usually defined as a creatinine clearance below 30 to 35 mL per minute.⁷ In practice, a transient bump in serum creatinine after infusion is common and expected. One retrospective analysis of osteoporosis patients found an average creatinine increase of 0.04 mg/dL, and acute kidney injury occurred in about 2.2 percent of infusions, with two of those patients progressing to chronic kidney problems due to additional health conditions.⁸

A larger dataset looking at nearly a thousand infusions found acute kidney injury within 14 days in about 4.6 percent of cases, though severe kidney injury requiring ongoing dialysis was rare. That study also found that the standard prescribing cutoff for kidney function had poor sensitivity for predicting who would actually develop problems.⁹ The practical takeaway: staying well hydrated before and after your infusion matters, and your doctor should check kidney function before each dose. In clinical trials where the drug was given according to prescribing guidelines, long-term kidney function decline was not observed even in elderly, frail patients with some preexisting renal impairment.⁷

An analysis of adverse events reported to a major safety database found that the most commonly reported kidney-related issue with zoledronic acid was renal tubular necrosis, and that most renal adverse events occurred either within the first 30 days of use or after more than 360 days on the drug, suggesting two distinct vulnerability windows.

Heart Rhythm and Cardiovascular Risk

An early signal from the landmark HORIZON trial raised questions about whether zoledronic acid might increase the risk of atrial fibrillation, an irregular heart rhythm that can raise the risk of stroke. Subsequent research has tried to nail down how real and how large this risk is. A meta-analysis and systematic review of randomized trials found that the overall risk ratio for cardiovascular events with zoledronic acid for osteoporosis versus placebo was 1.15, a statistically significant but modest increase.¹⁰ When the researchers drilled into specific categories, the risk of major adverse cardiovascular events like heart attack and stroke was not significantly elevated. But arrhythmias as a group were, with about a 30 percent relative increase, and atrial fibrillation specifically showed a trend toward increased risk that hovered at the edge of statistical significance.¹⁰

A separate propensity-matched cohort study comparing zoledronic acid directly with denosumab (a different osteoporosis drug that works through a different mechanism) found a modestly higher rate of atrial fibrillation in the first year among zoledronic acid users: about 18.6 per 1,000 person-years versus 14.9 for denosumab.¹¹ If you already have a history of heart rhythm issues, this is worth discussing with your doctor, even if the absolute added risk is small for most people.

Calcium Drops After Infusion

Zoledronic acid works by shutting down the cells that break down bone. When those cells suddenly go quiet, calcium that would normally be released from bone into the bloodstream stays locked in place, and serum calcium can dip. For most people this is clinically trivial, but in someone who enters the infusion already low on calcium or vitamin D, the drop can become symptomatic: tingling around the mouth, muscle cramps, spasms, and in severe cases, more dangerous complications.

Guidelines stress that calcium and vitamin D levels should be checked and corrected before each infusion, and that supplementation should continue afterward.¹² When those precautions are followed, clinically significant hypocalcemia becomes quite rare. In one study of 75 patients given zoledronic acid for Paget’s disease after educational efforts to ensure adequate calcium and vitamin D supplementation, only one patient developed low calcium, which resolved within a week with oral calcium.¹³

The risk is heightened in people transitioning from denosumab (brand name Prolia) to zoledronic acid. Denosumab causes a rebound surge in bone breakdown when it wears off, and giving zoledronic acid in that transitional window can create unpredictable swings. One case report described a woman who developed severe trismus, muscle twitching, and spasms about 10 hours after receiving zoledronic acid following denosumab, despite having normal calcium levels at the time of infusion. Her full recovery took two months.

Eye Inflammation

This one catches people by surprise because it seems so disconnected from a bone drug. Zoledronic acid can trigger acute anterior uveitis, an inflammation of the front chamber of the eye that causes a red, painful eye and sensitivity to light. In one clinical study, the incidence was 0.8 percent among people receiving zoledronate, with symptoms appearing an average of three days after infusion.¹⁴ All cases occurred in the drug arm, and none in the placebo group.

Most cases resolve with standard treatment like steroid eye drops, but occasionally the inflammation is more aggressive. One report described a 68-year-old woman who developed a severe constellation of corneal inflammation, uveitis with bleeding into the eye, scleritis, and orbital inflammation beginning just 12 hours after her first infusion.¹⁵ If you develop eye pain, redness, or blurred vision in the days following a Reclast infusion, it warrants a prompt eye exam rather than waiting it out.

Drug Holidays and How Long the Drug Keeps Working

Bisphosphonates are unusual drugs in that they bind directly into bone mineral and stay there for years after you stop taking them. This built-in reservoir is why doctors can recommend a “drug holiday,” a planned break from treatment, after a certain number of years on the medication. The goal is to reduce the risk of duration-dependent complications like atypical fractures and jaw osteonecrosis while maintaining much of the fracture protection.¹⁶

For zoledronic acid specifically, the landmark HORIZON extension trial compared six years of continuous treatment to three years of treatment followed by three years of placebo. Patients who received six years had a significantly lower rate of spinal compression fractures compared with those who stopped at three, roughly 3 percent versus 6 percent.¹⁷ For hip fractures, nonvertebral fractures, and overall clinical fractures, however, the rates were statistically indistinguishable between the two groups.¹⁷ This suggests that three years of zoledronic acid leaves enough drug in the skeleton to protect against most fracture types for at least a few additional years, though the spine may benefit from continued treatment.

A broader meta-analysis of bisphosphonate drug holidays confirmed that discontinuing treatment did not significantly raise the risk of hip or any clinical fracture compared with continuing.¹⁸ But subgroup analyses showed that women who had particularly low hip bone density at the end of their initial treatment period benefited more from staying on the drug. Current practice recommendations typically suggest a holiday of up to three years after an initial treatment course with zoledronic acid, derived primarily from the HORIZON extension data, though the ideal holiday length remains debated.¹⁹ The decision usually comes down to individual fracture risk: if your bones are still quite fragile after three years, continuing may be the better choice; if your bone density has improved substantially, a break is reasonable.

Why Patients Often Prefer Reclast Despite the Side Effects

One of the underappreciated aspects of Reclast is that, paradoxically, its once-yearly dosing schedule tends to improve how consistently people actually use their osteoporosis medication. Daily or weekly oral bisphosphonates come with fussy instructions (take on an empty stomach, stay upright for 30 minutes, wait before eating) and a dropout rate that climbs steeply after the first year. Studies on adherence show that people given annual zoledronic acid infusions have higher persistence rates than those on more frequent oral regimens, and patients generally prefer the less frequent dosing.²⁰ That matters because a drug you actually take consistently will protect your bones more effectively than a theoretically better drug gathering dust in your medicine cabinet.

There is a treatment benefit beyond six years that starts to plateau. Clinical data found minimal additional advantage in continuing zoledronic acid beyond six years of use, suggesting there is a ceiling on how much cumulative bone protection the drug delivers before the risk-benefit balance tips. For most people, the practical treatment arc involves three to six years of active infusions, a drug holiday of a few years with monitoring, and a reassessment of whether to resume based on how bone density and fracture risk look at that point.

The Denosumab-to-Reclast Transition Problem

A growing number of patients are being switched from denosumab to zoledronic acid rather than starting on Reclast from scratch, and this transition creates its own set of complications. Denosumab works through a completely different mechanism: it blocks a signaling protein that activates bone-destroying cells, and when it wears off, those cells come roaring back. The rebound bone loss after stopping denosumab can be rapid and severe, sometimes causing multiple vertebral fractures in the months after the last dose.

Zoledronic acid is often chosen as a “consolidation” therapy to prevent this rebound, but the timing is tricky. Give it too early and you risk stacking side effects. Give it too late and the rebound window has already opened. As the case report of the patient who developed severe muscle spasms and needed two months to recover illustrates, even patients with normal calcium and vitamin D levels can have unexpected reactions in this transitional period. This is an area where the evidence is still catching up with clinical practice, and if you are making this switch, close monitoring in the weeks after infusion is especially important.